Select Publications

Journal articles

Shen I; Stojanova J; Yeo M; Olsen N; Lockart I; Wang M; Roggeveld J; Heerspink HJL; Greenfield JR; Day R; Danta M, 2024, 'A potential novel treatment for cirrhosis-related ascites: Empagliflozin is safe and tolerable in advanced chronic liver disease', British Journal of Clinical Pharmacology, 90, pp. 2529 - 2538, http://dx.doi.org/10.1111/bcp.16139

Patel SK; Fourlanos S; Greenfield JR, 2024, 'Atypical Diabetes: What Have We Learned and What Does the Future Hold? Diabetes Care 2024;47:770–781', Diabetes Care, 47, http://dx.doi.org/10.2337/dc24-1388

Brzozowska MM; Bliuc D; Mazur A; Baldock PA; Eisman JA; Greenfield JR; Center JR, 2024, 'Correction: Sex-differential testosterone response to long-term weight loss (International Journal of Obesity, (2024), 10.1038/s41366-024-01591-7)', International Journal of Obesity, 48, pp. 1514, http://dx.doi.org/10.1038/s41366-024-01597-1

Sriravindrarajah A; Hurwitz J; Lim E; Greenfield JR, 2024, 'Hyperglycemia secondary to phosphatidylinositol-3 kinase (PI3K) inhibition', Endocrinology, Diabetes and Metabolism Case Reports, 2024-October, http://dx.doi.org/10.1530/EDM-24-0040

Frampton R; Snaith JR; Hocking S; Holmes-Walker J; Olsen N; Greenfield JR, 2024, 'Reducing cardiometabolic risk with semaglutide in type 1 diabetes (RESET1): Study protocol of a phase 2 double-blinded randomised placebo-controlled trial', Diabetic Medicine, 41, http://dx.doi.org/10.1111/dme.15377

Brzozowska MM; Bliuc D; Mazur A; Baldock PA; Eisman JA; Greenfield JR; Center JR, 2024, 'Sex-differential testosterone response to long-term weight loss', International Journal of Obesity, 48, pp. 1481 - 1488, http://dx.doi.org/10.1038/s41366-024-01591-7

de Oliveira Costa J; Lin J; Milder TY; Greenfield JR; Day RO; Stocker SL; Neuen BL; Havard A; Pearson SA; Falster MO, 2024, 'Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia', Diabetes, Obesity and Metabolism, 26, pp. 2787 - 2795, http://dx.doi.org/10.1111/dom.15597

FRAMPTON R; SNAITH JR; HOCKING SL; GREENFIELD J, 2024, '787-P: Reducing Cardiometabolic Risk with Semaglutide in Type 1 Diabetes (RESET1)—A Double-Blinded Randomized Placebo-Controlled Trial (Study Protocol)', Diabetes, 73, http://dx.doi.org/10.2337/db24-787-p

O'Donnell JEM; Hastings LA; Briody JN; Chan CL; Colombo C; Douglas TA; Freedman SD; Gonska T; Greenfield JR; Leung DH; Lim AYL; Moran A; Prentice BJ; Putman MS; Trotter M; Tullis E; Westall GP; Verge CF; Wainwright CE; Ooi CY; Engelhardt JF; Katz T; King S; Lewindon PJ; Matson AG; McDonald CM; Moheet A; Narkewicz MR; Oliver M; Ramm GA; Sellers ZM; Wilschanski M, 2024, 'SHIFTing goals in cystic fibrosis—managing extrapulmonary disease in the era of CFTR modulator therapy; Proceedings of the International Shaping Initiatives and Future Trends (SHIFT) Symposium', Pediatric Pulmonology, 59, pp. 1661 - 1676, http://dx.doi.org/10.1002/ppul.26970

Forner P; Snaith J; Greenfield JR, 2024, 'Prescribing patterns of adjunctive therapy for the treatment of type 1 diabetes mellitus among Australian endocrinologists', Internal Medicine Journal, 54, pp. 779 - 785, http://dx.doi.org/10.1111/imj.16312

Milder TY; Stocker SL; Baysari MT; Day RO; Greenfield JR, 2024, '‘We are somehow fixated on this being a diabetes drug’: a qualitative study exploring the views of cardiologists and nephrologists about sodium-glucose cotransporter 2 inhibitor initiation', Internal Medicine Journal, 54, pp. 559 - 567, http://dx.doi.org/10.1111/imj.16203

Lasschuit JWJ; Center JR; Greenfield JR; Tonks KTT, 2024, 'Effect of denosumab on inflammation and bone health in active Charcot foot: A phase II randomised controlled trial', Journal of Diabetes and its Complications, 38, http://dx.doi.org/10.1016/j.jdiacomp.2024.108718

Patel SK; Fourlanos S; Greenfield JR, 2024, 'Classification of type 1 diabetes: A pathogenic and treatment-based classification', Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 18, http://dx.doi.org/10.1016/j.dsx.2024.102986

Raven LM; Brown C; Greenfield JR, 2024, 'Considerations of delayed gastric emptying with peri-operative use of glucagon-like peptide-1 receptor agonists', Medical Journal of Australia, 220, pp. 14 - 16, http://dx.doi.org/10.5694/mja2.52170

Muir CA; Kuang W; Muthiah K; Greenfield JR; Raven LM, 2024, 'Association of early post-transplant hyperglycaemia and diabetes mellitus on outcomes following heart transplantation', Diabetic Medicine, http://dx.doi.org/10.1111/dme.15441

Lamaro BD; Greenfield JR; Snaith JR, 2024, 'Can Unmet Needs Be Addressed by Adjunctive Therapies? Findings from a Patient Perspectives Survey in Adults with Type 1 Diabetes', Journal of Patient Experience, 11, http://dx.doi.org/10.1177/23743735241257811

Milder TY; Lin J; Pearson SA; de Oliveira Costa J; Neuen BL; Pollock C; Jun M; Greenfield JR; Day RO; Stocker SL; Brieger D; Falster MO, 2024, 'Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?', Diabetes, Obesity and Metabolism, http://dx.doi.org/10.1111/dom.16061

Milder TY; Lin J; Pearson SA; Greenfield JR; Day RO; Stocker SL; Neuen BL; Falster MO; de Oliveira Costa J, 2024, 'Use of, time to, and type of first add-on anti-hyperglycaemic therapy to metformin in Australia, 2018–2022', British Journal of Clinical Pharmacology, http://dx.doi.org/10.1111/bcp.16231

Hayes AG; Penny MJ; Aivazian K; Greenfield JR, 2024, 'Acute Interstitial Nephritis and Oxalate Nephropathy After Rapid Pasireotide Response in Treatment-resistant Acromegaly.', JCEM Case Rep, 2, pp. luae071, http://dx.doi.org/10.1210/jcemcr/luae071

Raven LM; Muir CA; Deveza RC; Kessler Iglesias C; Bart NK; Muthiah K; Kotlyar E; Hayward CS; Macdonald PS; Jabbour A; Greenfield JR, 2024, 'Effect of sodium glucose cotransporter 2 inhibition immediately prior to heart transplantation', JHLT Open, 5, pp. 100088 - 100088, http://dx.doi.org/10.1016/j.jhlto.2024.100088

Raven LM; Cao JY; Macdonald PS; Jabbour A; Greenfield JR, 2024, 'Fournier’s gangrene in recent transplant recipient on empagliflozin', JHLT Open, 4, pp. 100060 - 100060, http://dx.doi.org/10.1016/j.jhlto.2024.100060

Jeyakumar S; Jeyakumar R; Robson D; Honeysett L; Raven L; Campos Deveza e Silva R; Jabbour A; Kotlyar E; Keogh A; Greenfield J; MacDonald P; Hayward C; Muthiah K, 2024, 'Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in End-Stage Heart Failure Patients Considered for Heart Transplantation', The Journal of Heart and Lung Transplantation, 43, pp. S106 - S106, http://dx.doi.org/10.1016/j.healun.2024.02.213

Raven LM; Muir CA; Kessler Iglesias C; Bart NK; Muthiah K; Kotlyar E; Hayward CS; Macdonald PS; Jabbour A; Greenfield JR, 2024, 'Safety of Sodium Glucose Co-Transporter 2 Inhibitor Exposure Prior to Heart Transplantation', The Journal of Heart and Lung Transplantation, 43, pp. S148 - S149, http://dx.doi.org/10.1016/j.healun.2024.02.302

Raven LM; Stoita A; Feller RB; Brown C; Greenfield JR, 2023, 'Delayed Gastric Emptying with Perioperative Use of Glucagon-like Peptide-1 Receptor Agonists', American Journal of Medicine, 136, pp. e233 - e234, http://dx.doi.org/10.1016/j.amjmed.2023.07.016

Brzozowska MM; Isaacs M; Bliuc D; Baldock PA; Eisman JA; White CP; Greenfield JR; Center JR, 2023, 'Effects of bariatric surgery and dietary intervention on insulin resistance and appetite hormones over a 3 year period', Scientific Reports, 13, http://dx.doi.org/10.1038/s41598-023-33317-6

Milder TY; Milder DA; Greenfield JR; Day RO, 2023, 'Sodium-Glucose Cotransporter 2 Inhibitor-Associated “Ketoacidosis” Versus “Diabetic Ketoacidosis”: The Importance of Accurate Terminology', Drug Safety, 46, pp. 1303 - 1305, http://dx.doi.org/10.1007/s40264-023-01358-5

Chavali S; Barua S; Adji A; Robson D; Raven LM; Greenfield JR; Eckford H; Macdonald PS; Hayward CS; Muthiah K, 2023, 'Safety and tolerability of sodium-glucose cotransporter-2 inhibitors in bridge-to-transplant patients supported with centrifugal-flow left ventricular assist devices', International Journal of Cardiology, 391, http://dx.doi.org/10.1016/j.ijcard.2023.131259

Hayes AG; Raven LM; Viardot A; Kotlyar E; Greenfield JR, 2023, 'SGLT2 Inhibitor-Induced Ketoacidosis in a Patient Without Diabetes', Diabetes Care, 47, pp. e4 - e5, http://dx.doi.org/10.2337/dc23-1903

Milder TY; Greenfield JR; Milder DA, 2023, 'Peri-procedural ketoacidosis risk with sodium-glucose cotransporter 2 inhibitor use in people without diabetes', Anaesthesia, 78, pp. 1418 - 1419, http://dx.doi.org/10.1111/anae.16068

Snaith JR; Olsen N; Kowalski G; Bruce C; Holmes-Walker J; Greenfield JR, 2023, 'OR18-03 Peripheral But Not Hepatic Insulin Resistance Associates With Adverse Vascular And Metabolic Health In Type 1 Diabetes: A Possible Target For Adjunctive Therapy', Journal of the Endocrine Society, 7, http://dx.doi.org/10.1210/jendso/bvad114.895

Raven LM; Muir CA; Kessler Iglesias C; Kotlyar E; Muthiah K; Bart NK; Macdonald PS; Hayward CS; Jabbour A; Greenfield JR, 2023, 'THU298 Effect Of SGLT2 Inhibition On Metabolic, Cardiac And Renal Outcomes In Heart Transplant Recipients (EMPA-HTx study): Protocol And Study Design', Journal of the Endocrine Society, 7, http://dx.doi.org/10.1210/jendso/bvad114.733

Raven LM; Muir CA; Greenfield JR, 2023, 'Sodium glucose cotransporter 2 inhibitor-induced ketoacidosis is unlikely in patients without diabetes', Medical Journal of Australia, 219, pp. 293 - 294, http://dx.doi.org/10.5694/mja2.52067

Sheu A; Blank RD; Tran T; Bliuc D; Greenfield JR; White CP; Center JR, 2023, 'Associations of Type 2 Diabetes, Body Composition, and Insulin Resistance with Bone Parameters: The Dubbo Osteoporosis Epidemiology Study', JBMR Plus, 7, http://dx.doi.org/10.1002/jbm4.10780

Raven LM; Muir CA; Pouliopoulos J; Hayward CS; Macdonald PS; Greenfield JR; Jabbour A, 2023, 'Metabolic Sequelae of Everolimus Treatment After Cardiac Transplant: A Hypothesis-Generating Study', Heart Lung and Circulation, 32, pp. 1076 - 1079, http://dx.doi.org/10.1016/j.hlc.2023.05.014

Lin J; Pearson SA; Greenfield JR; Park KH; Havard A; Brieger D; Day RO; Falster MO; de Oliveira Costa J, 2023, 'Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014–2022)', European Journal of Clinical Pharmacology, 79, pp. 1239 - 1248, http://dx.doi.org/10.1007/s00228-023-03539-8

Chowdhury G; Carland JE; Kumar S; Olsen N; Graham G; Kumarasinghe G; Hayward CS; Greenfield JR; Macdonald P; Day RO; Stocker SL, 2023, 'The safe use of metformin in heart failure patients both with and without T2DM: A cross-sectional and longitudinal study', British Journal of Clinical Pharmacology, 89, pp. 2603 - 2613, http://dx.doi.org/10.1111/bcp.15737

RAVEN LM; MUIR CA; POULIOPOULOS JIM; MACDONALD PS; JABBOUR A; GREENFIELD J, 2023, '1438-P: Diabetes after Cardiac Transplant with Low-Dose Everolimus and Tacrolimus', Diabetes, 72, http://dx.doi.org/10.2337/db23-1438-p

Lasschuit JWJ; Greenfield JR; Tonks KTT, 2023, 'Response to the Letter to the Editor regarding “Contribution of peripheral neuropathy to poor bone health in the feet of people with type 2 diabetes mellitus”', Acta Diabetologica, 60, pp. 713 - 714, http://dx.doi.org/10.1007/s00592-023-02052-9

Raven LM; Muir CA; Macdonald PS; Hayward CS; Jabbour A; Greenfield JR, 2023, 'Diabetes medication following heart transplantation: a focus on novel cardioprotective therapies—a joint review from endocrinologists and cardiologists', Acta Diabetologica, 60, pp. 471 - 480, http://dx.doi.org/10.1007/s00592-022-02018-3

Raven LM; Muir CA; Kessler Iglesias C; Bart NK; Muthiah K; Kotlyar E; Macdonald P; Hayward CS; Jabbour A; Greenfield JR, 2023, 'Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): Protocol for a randomised controlled trial', BMJ Open, 13, http://dx.doi.org/10.1136/bmjopen-2022-069641

Cooper B; Blaker K; Greenfield JR, 2023, 'Olanzapine-induced multifactorial chylomicronaemia syndrome: a rare but important complication', ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS, 2023, http://dx.doi.org/10.1530/EDM-22-0225

Sheu A; Greenfield JR; White CP; Center JR, 2023, 'Contributors to impaired bone health in type 2 diabetes', Trends in Endocrinology and Metabolism, 34, pp. 34 - 48, http://dx.doi.org/10.1016/j.tem.2022.11.003

Snaith JR; Greenfield JR; Malozowski S; Weghuber D; Kelly AS; Arslanian S, 2023, 'Once-Weekly Semaglutide in Adolescents with Obesity', New England Journal of Medicine, 388, pp. 1145, http://dx.doi.org/10.1056/NEJMc2300510

Raven LM; Greenfield JR; Muir CA, 2023, 'Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes.', JCEM Case Rep, 1, pp. luac017, http://dx.doi.org/10.1210/jcemcr/luac017

Koay YC; Coster ACF; Chen DL; Milner B; Batarseh A; O’Sullivan JF; Greenfield JR; Samocha-Bonet D, 2022, 'Metabolomics and Lipidomics Signatures of Insulin Resistance and Abdominal Fat Depots in People Living with Obesity', Metabolites, 12, pp. 1272, http://dx.doi.org/10.3390/metabo12121272

Moxham R; Greenfield JR; Viardot A; Wu KHC, 2022, 'Tip of the iceberg: are we missing undiagnosed patients with maturity onset diabetes of the young?', Internal Medicine Journal, 52, pp. 2011 - 2012, http://dx.doi.org/10.1111/imj.15948

Patel SK; Ma CS; Bell KJ; Oram R; Hagopian WA; Fourlanos S; Greenfield JR, 2022, 'Immunophenotype and genetic risk scores to improve autoantibody negative type 1 diabetes classification: study protocol', International Journal of Clinical Trials, 9, pp. 293 - 293, http://dx.doi.org/10.18203/2349-3259.ijct20222690

Tiwary M; Milder TY; Stocker SL; Day RO; Greenfield JR, 2022, 'Sodium-glucose co-transporter 2 inhibitor therapy: use in chronic kidney disease and adjunctive sodium restriction', Internal Medicine Journal, 52, pp. 1666 - 1676, http://dx.doi.org/10.1111/imj.15727

Raven LM; Morris P; Greenfield JR, 2022, 'Hyperglycaemia induced by gamma-butyrolactone', Diabetic Medicine, 39, http://dx.doi.org/10.1111/dme.14850

Snaith JR; Greenfield JR, 2022, 'Sodium–glucose cotransporter 2 inhibitors in type 1 diabetes: a missed opportunity for cardiovascular protection?', Medical Journal of Australia, 217, pp. 126 - 128, http://dx.doi.org/10.5694/mja2.51637


Back to profile page